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Abstract
Immune-mediated ataxias account for a substantial number of sporadic otherwise idiopathic ataxias. Despite some well-
characterised entities such as paraneoplastic cerebellar degeneration where diagnostic markers exist, the majority of
immune ataxias remained undiagnosed and untreated. We present here our experience in the treatment of suspected
primary autoimmune cerebellar ataxia (PACA) using mycophenolate. All patients reported attend the Sheffield Ataxia
Centre on a regular basis and had undergone extensive investigations, including genetic testing using next-generation
sequencing, with other causes of ataxia excluded. The diagnosis of PACA was strongly suspected based on investigations,
pattern of disease progression, and cerebellar involvement. Patients were treated with mycophenolate and monitored using
MR spectroscopy of the cerebellar vermis. Thirty patients with PACA are reported here. Of these, 22 received mycophe-
nolate (group 1). The remaining 8 were not on treatment (group 2-control group). Out of the 22 treated patients, 4
underwent serial MR spectroscopy prior to starting treatment and thus were used as controls making the total number
of patients in the control group 12. The mean change of the MRS within the vermis (NAA/Cr area ratio) in the treatment
group was + 0.144 ± 0.09 (improved) and in the untreated group − 0.155 ± 0.06 (deteriorated). The difference was signif-
icant. We also demonstrated a strong correlation between the spectroscopy and the SARA score. We have demonstrated the
effectiveness of mycophenolate in the treatment of PACA. The results suggest that immune-mediated ataxias are poten-
tially treatable, and that there is a need for early diagnosis to prevent permanent neurological deficit. The recently
published diagnostic criteria for PACA would hopefully aid the diagnosis and treatment of this entity.
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Introduction
Immune-mediated ataxias include paraneoplastic cerebellar
degeneration (PCD), gluten ataxia (GA) and post-infective
cerebellitis. Unlike PCD, GA and post-infective cerebellitis
where an antigenic trigger is known, in most suspected auto-
immune ataxias, the antigenic trigger is not known and any
associated neuronal antibodies are not well characterized or
proven pathogenic. The term Primary Autoimmune
Cerebellar Ataxia (PACA) was introduced to describe this
later group [1].
Progress in our ability to genetically characterise the
ataxias, using next-generation sequencing has, paradoxically,
also resulted in appreciating that the majority of idiopathic
sporadic ataxias are not due to a genetic defect. Adult-onset
idiopathic sporadic ataxias account for 20% of all ataxias [2].
We suspect that a substantial number of such patients have
an immune-mediated ataxia along the lines of PACA. This
suspicion is not just based on the absence of any genetic defect
but also the acute/subacute onset of ataxia (unlike genetic
ataxias), the predilection for vermian involvement, the con-
current presence of other autoimmune diseases and additional
clues from other investigations (e.g. CSF pleocytosis, OCB’s,
presence of neuronal and non-neuronal antibodies). Criteria
aiding the diagnosis of PACA have recently been published
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[3]. Here, we report our experience in treating patients
suspected of having PACA using mycophenolate.
Material and Methods
Patient Selection
All patients reported here attend the Sheffield Ataxia Centre
on a regular basis. These patients have undergone extensive
investigations for an underlying cause of their ataxia, includ-
ing genetic testing using NGS and other tests. Full details of
such investigations have been published previously [2]. In all
patients reported here, other causes of ataxia were excluded
and the diagnosis of PACA was suspected based on the acute/
subacute onset of ataxia, the predilection for vermian involve-
ment both clinically and on imaging, the concurrent presence
of other autoimmune diseases and additional clues from other
investigations (e.g. CSF pleocytosis, OCB’s, presence of neu-
ronal and non-neuronal antibodies) [3]. This information is
summarised in Table 1.
It is our current practice to treat patients with suspected PACA
who appear to follow a progressive course with mycophenolate.
In this report, we have excluded patients with other forms of
immune-mediated ataxias such as paraneoplastic cerebellar de-
generation and gluten ataxia where the treatment is different.
All patients were provided with patient information leaflet
on PACA (produced for Sheffield Ataxia Centre, Sheffield
Teaching Hospitals NHS Trust) and a leaflet about mycophe-
nolate (produced by Arthritis Research UK). Mycophenolate
was introduced at 500 mg twice daily and if tolerated and with
normal safety blood monitoring (done every 2 weeks), the
dose was increased to 1 g twice daily at 1 month. Patients
were re-assessed on a 4 monthly basis with repeat safety blood
monitoring done every 4 months thereafter.
MR Spectroscopy
In addition to volumetric 3 T MR imaging, all patients
underwent single-voxel H1 MR spectroscopy (MRS) of the
cerebellum. This imaging protocol is in clinical use as part
of the investigation of all patients with cerebellar ataxia at-
tending the Sheffield Ataxia Centre. The brain imaging pro-
tocol for structural, volumetric and spectroscopy studies has
been previously described [4]
Patients underwent baseline MRI including MRS of the
vermis measuring N-acetyl-aspartate to creatine (NAA/Cr) ar-
ea ratio, reflecting metabolic activity. Repeat MRS was per-
formed after at least a year of treatment with mycophenolate.
In common with other immune-mediated ataxias, the cerebel-
lar vermis is primarily involved in PACA, and therefore, MRS
results reported here are measurements from the cerebellar
vermis [4, 5].
Correlation of MRS with the Scale for the Assessment
and Rating of Ataxia (SARA)
Forty consecutive patients with different types of ataxias, in-
cluding genetic, immune and degenerative (cerebellar variant
of multiple system atrophy), were included in the analysis for
the purpose of this correlation. All of these patients had un-
dergone MRS and SARA score as part of their clinical assess-
ment whilst attending their follow-up appointments at the
Sheffield Ataxia Centre.
Statistical Analysis
Change in mean values between the groups was compared
with Student’s two-tailed t test for unpaired samples. A value
of p < 0.05 was considered significant. For the correlation
Table 1 Clinical characteristics
of 30 patients with PACA.
Cerebellar atrophy was rated as
1 =mild, 2 =moderate, 3 = severe
with a mean score for vermian
atrophy 1.44 vs hemispheric
atrophy of 1. This demonstrates
the preferential involvement of
the vermis in PACA. IDDM
insulin dependent diabetes
mellitus, PA pernicious anaemia,
SPS stiff person syndrome, SLE
systemic lupus erythematosus
Average age at onset of ataxia 56 years (range 18 to 83)
Average age at the time of this report 63 years (range 20 to 86)
Average duration of ataxia 7 years (range 2 to 20)
additional autoimmune diseases 100% (10 thyroid disease, 5 IDDM, 4 PA,
3 Sjogren’s, 2 SPS, 1 SLE, 1 scleroderma,
1 RA, 1 Crohn’s, 1 myositis, 1 vitiligo)
CSF oligoclonal bands 5/10 (50%)
auto-antibodies 26/30 (87%) (12 thyroid peroxidase,
5 low level anti-GAD, 4 intrinsic factor,
3 anti-Ro, 1 ANA/dsDNA, 1 centromere, 1 anti-CCP)
Subacute presentation 21/30 (70%)
Acute presentation 4/30 (13%)
Gait ataxia 100%
Abnormal vermian NAA/Cr 100% (mean NAA/Cr ratio 0.82)
Degree of vermian atrophy 1.44 (1 mild, 2 moderate, 3 severe)
Degree of hemispheric atrophy 1
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analysis, Spearman’s rho was used as SARA is an ordinal
measure.
Results
Demographics
The clinical characteristics of the 30 patients with PACA are
summarised in Table 1. A total of 30 consecutive patients with
PACA were included in the analysis. Of these, 22 patients
started treatment with mycophenolate between January 2015
and the time of this report. Out of these 22 patients, 4 already
had 2 MRS scans at 2 time points prior to starting the treat-
ment, so their pre-treatment data was used as part of the con-
trol group’s MRS data which thus comprised 12 patients in
total (the 4 that were subsequently treated plus 8 patients that
are still on no treatment). The reasons for no treatment in the
control group included delayed diagnosis of PACA and reluc-
tance by the patient and family for the use of immunosuppres-
sive medication. Some patients did not feel that their ataxia
was bad enough to warrant treatment with mycophenolate.
This was also reflected by the fact that the control group had
higher NAA/Cr vermian baseline spectroscopy when com-
pared to the treatment group.
The mean age of the 2 groups was 64.3 ± 14.4 years
(treated) vs 63.3 ± 20.6 (untreated). The mean time difference
between the baseline and the secondMRS scanwas 24months
in the treated group and 15.8 months in the untreated group.
The mean duration of the ataxia in the treated group was
6.73 years (range 2–20) and in the untreated group 9.42 years
(range 2–20). None of the above differences were significant.
None of the patients in the treatment group had to stop
mycophenolate because of tolerability issues or side effects.
Treatment was well tolerated; the only adverse effects reported
were mild nausea (2 patients) after starting the medication.
This subsided within a few weeks or with reduction of the
dose.
Correlation of MRS with the SARA
There was a significant negative correlation using Spearman’s
rho between the sum of gait and stance scores (a reflection of
vermian functioning) from SARA Vs NAA/Cr area ratios
from MRS of the vermis. The correlation was highly signifi-
cant with the correlation coefficient rs = − 0.07, p =
0.00000129 (Fig. 1).
MRS Results
The mean change of the MRS within the vermis (NAA/Cr
area ratio) in the treatment group was + 0.144 ± 0.09 and in
the untreated group − 0.155 ± 0.06. The difference was
significant (p < 0.0001 by Student’s t test). Fig. 2 illustrates
these changes. Fig. 3 demonstrates the change from baseline
in the 2 groups. In all 22 patients treated, the MRS within the
vermis improved whereas in all of 12 patients untreated, the
MRS worsened. For the 4 patients for which MRS data were
available before and after treatment, Fig. 4 illustrates these
changes. The MRS changes were associated with clinical im-
provement, and all the patients in the treatment group have
continued treatment with mycophenolate.
Discussion
We have demonstrated for the first time that treatment with
mycophenolate in patients with suspected PACA results in
increased NAA/Cr area ratio of the cerebellar vermis as mea-
sured with MRS. Such increase is associated with clinical
improvement. We have demonstrated this by showing that
NAA/Cr area ratio from the vermis inversely correlates with
the SARA sub-score for gait and stance. This improvement
Fig. 1 Graph depicting significant negative correlation between the sum
of gait and stance scores from SARA (the higher the score the more
severe the ataxia) vs NAA/Cr area ratio from MRS of the vermis (the
higher the measurement, the better cerebellar functioning) in 40 patients
with various types of ataxias. The correlation was highly significant with
correlation coefficient rs = − 0.07, p = 0.00000129
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Fig. 2 Change in MRS (NAA/Cr area ratio, vertical axis) after treatment
(treated group) and in the untreated group. The difference was significant
p < 0.0001 by Student’s t test
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with the use of mycophenolate supports the notion of an au-
toimmune aetiology for PACA and also that the ataxia is par-
tially reversible with immunosuppression.
We selected mycophenolate for treating PACA as this
drug has been in clinical use for many years, initially for
the prophylaxis of acute rejection after organ transplanta-
tion and later to treat autoimmune diseases such as lupus
nephritis and systemic vasculitis [6]. Over the last 15 years,
we have gained experience with the use of this drug in
patients with immune-mediated neurological diseases in-
cluding neurological vasculitis, myasthenia gravis,
neurosarcoidosis, inflammatory neuropathies, autoimmune
encephalitis and neurological manifestations of gluten-
related diseases in the context of refractory coeliac disease.
Mycophenolate is well tolerated and serious side effects
are extremely rare. It can be titrated to the effective dose
(2 g per day) quickly, and its cost has been substantially
reduced since generic preparations have become available.
Our experience in investigating and monitoring over 2000
patients with progressive ataxias over the last 25 years helped
in the recognition of a cohort of patients suspected of having
PACA [1, 7].
The term PACA is restricted to those ataxias where an
antibody, if present, is not directly involved in the pathogen-
esis of the ataxia, neither does it act as a marker of another
well-characterised immune ataxia (e.g. anti-Yo in the context
of paraneoplastic ataxia). Such antibodies may not be neuro-
nal but simply reflect additional autoimmune tendency (e.g.
thyroid antibodies, intrinsic factor). Recently, diagnostic
criteria for PACA have been published by an International
Task Force on Immune-Mediated Cerebellar Ataxias [3].
We can confirm that the patients reported here would fulfil
the diagnostic criteria for PACA as outlined in the Task Force
publication.
Retrospective studies looking at the treatment of immune
ataxias have utilized various immunomodulatory approaches
including intravenous immunoglobulins, steroids, plasma ex-
change and rituximab [8]. One such retrospective study in-
cluded 118 patients with suspected immune-mediated ataxias,
55 of which had non-paraneoplastic ataxia [9]. All patients
had received some form of immunotherapy, and neurological
improvement was reported in 54 patients. Regression analysis
revealed that improvements were significantly more common
amongst patients with non-paraneoplastic ataxias. There are
no randomised control studies demonstrating the effectiveness
of any of the above immunomodulatory approaches.
At the Sheffield Ataxia Centre, we prefer to avoid the use
of long-term steroids in the context of PACA because of the
potential long-term adverse effects. Short course of high dose
steroids, used by some, is unlikely to demonstrate any imme-
diate benefit and such an approach may create an erroneous
impression that the disease is not responsive to
immunomodulation. However, a subgroup of these patients
may follow a very aggressive and rapidly progressive course.
In this situation, steroids and intravenous immunoglobulins
may be used at presentation before mycophenolate has its full
effect. Such successful combinations of immunomodulation
that include mycophenolate have already been published as
case reports or small series [10–12].
We and others have usedMRS as a useful biological mark-
er of disease progression and disease response to therapeutic
interventions [3, 4, 13–16]. In the current study, we also
showed a correlation between MRS and SARA score. The
advantage of MRS as a monitoring tool is that it can be easily
performed as part of routine MR imaging, it is reproducible
and relies on objective measurements such as the NAA/Cr
area ratio. It therefore overcomes the disadvantages of the
clinical scales (interrater variability, fluctuation of ataxia
symptoms and signs due to fatigue, insensitive scales in se-
verely disabled patients and ceiling effect).
MRS of the vermis in particular is more reliable and repro-
ducible than that of the hemisphere as the lateral borders of the
vermis guide the positioning of the voxel. As the vermis is
primarily affected in immune ataxias including PACA, we
recommend NAA/Cr area ratio from the vermis as the main
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Fig. 4 Change in MRS (NAA/Cr area ratio) in the 4 patients that were
both in the control (baseline and 2nd MRS) and treatment groups (2nd
and 3rd MRS), showing deteriorating NAA/Cr prior to treatment and
improvement after treatment with mycophenolate
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Fig. 3 Change in MRS (NAA/Cr area ratio) from baseline in the treated
and untreated groups
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monitoring tool. Whilst volumetric analysis may provide an
accurate measure of cerebellar atrophy, atrophy may be con-
sidered as an end point of accumulated cerebellar insult,
whereas MRS is sensitive to cerebellar injury and potential
for recovery (cerebellar reserve).
There are limitations to this report. The results are obser-
vational and based on our experience in treating patients with
suspected PACA. To our knowledge, no randomized control
trial on the treatment of PACAhas ever been performed and as
ataxia is considered a rare disease such a study may be
difficult to perform in a single centre. Furthermore, the avail-
ability of MRS of the cerebellum is very limited in the UK.
In conclusion, we have demonstrated for the first time the
effectiveness of mycophenolate in increasing NAA/Cr area
ratio of the cerebellar vermis as measured with MRS in pa-
tients with PACA. This increase correlates with clinical im-
provement. We have also shown that NAA/Cr area ratio cor-
relates with a clinical scale of measuring ataxia (SARA). The
results suggest that immune-mediated ataxias are potentially
treatable and that there is a need for early diagnosis to prevent
permanent neurological deficit and preserve cerebellar re-
serve. The recent publication of diagnostic criteria for PACA
will hopefully aid neurologists in considering this diagnosis
and treat with immunosuppression.
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